Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.
CXCR4
nuclear medicine
oncology
pharmacokinetics
positron emission tomography
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
received:
07
06
2022
revised:
02
07
2022
accepted:
07
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The C-X-C chemokine receptor 4 (CXCR4) is highly expressed in many subtypes of cancers, notably in several kidney-based malignancies. We synthesized, labeled, and assessed a series of radiotracers based on a previous high contrast PET imaging radiopharmaceutical [ Based on the design of BL02, a piperidine-based cationic linker (BL06) and several anionic linkers (tri-Aad (BL17); tri-D-Glu (BL20); tri-Asp (BL25); and tri-cysteic acid (BL31)) were substituted for the triglutamate linker. Additionally, the DOTA chelator was swapped for a DOTAGA chelator (BL30). Each radiotracer was labeled with Of all the evaluated radiotracers, [ [
Identifiants
pubmed: 35890397
pii: pharmaceutics14071502
doi: 10.3390/pharmaceutics14071502
pmc: PMC9316317
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Canadian Institutes for Health Research
ID : #FDN-148465
Références
Methods Mol Biol. 2013;993:81-94
pubmed: 23568465
J Nucl Med. 2005 Oct;46(10):1696-700
pubmed: 16204720
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455729
Org Lett. 2012 Oct 19;14(20):5218-21
pubmed: 23025410
Bioconjug Chem. 2008 Jan;19(1):201-10
pubmed: 18069778
Nucl Med Biol. 2018 Jul - Aug;62-63:18-30
pubmed: 29803076
EJNMMI Radiopharm Chem. 2021 Aug 25;6(1):29
pubmed: 34432147
J Chem Inf Model. 2013 Apr 22;53(4):948-57
pubmed: 23451981
Kidney Int. 2005 Mar;67(3):969-76
pubmed: 15698435
ChemMedChem. 2013 Mar;8(3):385-95
pubmed: 23361977
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
Theranostics. 2017 Feb 8;7(4):805-813
pubmed: 28382155
Nucl Med Biol. 2007 Aug;34(6):633-41
pubmed: 17707803
J Med Chem. 2005 Jan 13;48(1):141-51
pubmed: 15634008
Med Res Rev. 1996 Jan;16(1):3-50
pubmed: 8788213
Mol Pharm. 2021 Jan 4;18(1):187-197
pubmed: 33253591
Mini Rev Med Chem. 2005 Jun;5(6):585-93
pubmed: 15974936
Eur J Pharm Biopharm. 2019 Jul;140:109-120
pubmed: 31082509
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):123-135
pubmed: 31482426
Sci Rep. 2017 Oct 25;7(1):13971
pubmed: 29070853
Cancers (Basel). 2021 Nov 25;13(23):
pubmed: 34885030
Curr Opin Endocrinol Diabetes Obes. 2010 Feb;17(1):69-76
pubmed: 19901831
J Physiol. 1963 Apr;166:1-14
pubmed: 14024354
Clin Cancer Res. 2016 Jan 1;22(1):187-99
pubmed: 26350264
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418
pubmed: 11185661
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2680-3
pubmed: 20303751
Curr Drug Metab. 2018;19(11):892-901
pubmed: 29956618
Cancer Treat Rev. 2018 Nov;70:127-137
pubmed: 30173085
Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1125-38
pubmed: 20536274
J Nucl Med. 2015 Mar;56(3):410-6
pubmed: 25698782
Clin Cancer Res. 2013 Sep 1;19(17):4706-16
pubmed: 23690484
Nat Rev Cancer. 2004 Jul;4(7):540-50
pubmed: 15229479
Eur J Cancer. 2013 Jan;49(1):219-30
pubmed: 22683307
Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1136-43
pubmed: 15912401
J Nucl Med. 2005 Jun;46(6):1012-5
pubmed: 15937313
J Med Chem. 2019 May 23;62(10):4979-4990
pubmed: 31021628
J Pept Sci. 2015 Aug;21(8):680-7
pubmed: 26077723
Brief Bioinform. 2002 Mar;3(1):73-86
pubmed: 12002226
Blood. 2009 Jun 11;113(24):6215-24
pubmed: 18955566
Pharmacol Ther. 1996;72(1):25-36
pubmed: 8981569
Bioconjug Chem. 2017 Sep 20;28(9):2485-2492
pubmed: 28787147
Nucl Med Biol. 2021 Nov-Dec;102-103:1-11
pubmed: 34242948
Oncotarget. 2017 Oct 10;8(55):94619-94634
pubmed: 29212254
Clin Cancer Res. 2022 Apr 14;28(8):1628-1639
pubmed: 35078860
FASEB J. 2004 Aug;18(11):1240-2
pubmed: 15180966
Mol Pharm. 2016 May 2;13(5):1668-78
pubmed: 27010700
Mol Pharm. 2019 Nov 4;16(11):4688-4695
pubmed: 31545614
Int J Oncol. 2016 May;48(5):2124-34
pubmed: 26983776
EJNMMI Res. 2014 Dec;4(1):63
pubmed: 26116124
J Nucl Med. 2019 Jun;60(6):812-816
pubmed: 30504139
Mol Pharm. 2018 Aug 6;15(8):3502-3511
pubmed: 29920108
J Med Chem. 2001 Apr 26;44(9):1313-33
pubmed: 11311053